Toshiaki Ohashi
PhD
Senior Research Fellow, Drug Discovery
👥Biography 个人简介
Toshiaki Ohashi is a key innovator in the development of the DXd (deruxtecan) payload, an exatecan-derivative topoisomerase I inhibitor that powers the transformative T-DXd platform. His work on payload-linker chemistry achieved optimal drug-to-antibody ratios with maintained stability. The bystander killing effect of the membrane-permeable DXd payload has been a critical feature enabling activity in heterogeneous tumors.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Toshiaki Ohashi 的研究动态
Follow Toshiaki Ohashi's research updates
留下邮箱，当我们发布与 Toshiaki Ohashi（Daiichi Sankyo）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment